pacDNA is transforming gene regulation therapeutics with Brushield™, our proprietary oligonucleotide enhancer technology that addresses multiple challenges in a single, potent molecular construct. Brushield™ enhances nearly all forms of gene regulation agents, including antisense oligonucleotides (ASOs), splice correction agents, small interfering RNA (siRNA), and aptamers. As a novel single-entity polymer-nucleic acid conjugate, Brushield™ marks a significant departure from conventional positively charged carriers and lipid nanoparticles, overcoming many of their limitations. Notably, Brushield™ avoids renal clearance, enabling improved distribution to non-liver organs and tissues such as muscles and skin. It also evades neutralizing immunity, making it particularly powerful for developing drugs for long-term disease management. Built from proven safe pharmaceutical components, Brushield™ is highly manufacturable, customizable, and scalable for diverse delivery needs. In summary, he Brushield™ platform generates potent clinical leads with fewer side effects and lower dosage requirements, delivering transformative therapies to previously challenging non-liver targets